Integra LifeSciences (NASDAQ:IART) Stock Price Expected to Rise, Truist Financial Analyst Says

Integra LifeSciences (NASDAQ:IART) had its target price upped by stock analysts at Truist Financial from $14.00 to $19.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a “hold” rating on the life sciences company’s stock. Truist Financial’s target price suggests a potential downside of 3.65% from the company’s previous close.

A number of other brokerages have also recently commented on IART. Wells Fargo & Company boosted their price objective on Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a research note on Wednesday, May 6th. BMO Capital Markets began coverage on shares of Integra LifeSciences in a research note on Wednesday, July 8th. They set a “market perform” rating and a $19.00 price target on the stock. Argus upgraded Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a research note on Thursday, June 18th. Weiss Ratings upgraded shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 13th. Finally, Citigroup reiterated a “neutral” rating and issued a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a research note on Wednesday, July 8th. One analyst has rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Integra LifeSciences presently has a consensus rating of “Reduce” and a consensus target price of $18.33.

Integra LifeSciences Price Performance

IART traded up $0.94 during midday trading on Thursday, reaching $19.72. 125,476 shares of the company’s stock were exchanged, compared to its average volume of 889,287. The business’s 50-day moving average price is $16.68 and its 200 day moving average price is $12.98. The stock has a market capitalization of $1.53 billion, a PE ratio of -3.05, a P/E/G ratio of 1.27 and a beta of 1.22. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.38 and a quick ratio of 1.95. Integra LifeSciences has a 1-year low of $8.70 and a 1-year high of $20.00.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.13. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. The company had revenue of $391.92 million for the quarter, compared to analysts’ expectations of $381.81 million. During the same period last year, the company earned $0.41 EPS. The firm’s revenue for the quarter was up 2.4% compared to the same quarter last year. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. As a group, equities analysts anticipate that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Hedge Funds Weigh In On Integra LifeSciences

Several hedge funds and other institutional investors have recently modified their holdings of IART. Global Retirement Partners LLC bought a new stake in Integra LifeSciences in the 4th quarter valued at about $25,000. Osaic Holdings Inc. grew its stake in shares of Integra LifeSciences by 36.6% in the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after purchasing an additional 1,104 shares in the last quarter. GAMMA Investing LLC increased its stake in Integra LifeSciences by 145.9% during the 4th quarter. GAMMA Investing LLC now owns 6,307 shares of the life sciences company’s stock valued at $78,000 after buying an additional 3,742 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of Integra LifeSciences by 595.6% in the second quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock valued at $98,000 after acquiring an additional 6,814 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in Integra LifeSciences during the fourth quarter worth approximately $124,000. Institutional investors and hedge funds own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.